Cytochrome P450-dependent metabolism of l-deprenyl in monkey (Cercopithecus aethiops) and C57BL/6 mouse brain microsomal preparations

Journal of Neurochemistry

Volumn 86, Issue 5, 2003, Pages 1174-1180

  Dragoni, Stefania ^a   Bellik, Lydia ^a   Frosini, Maria ^a   Matteucci, Giacomo ^b   Sgaragli, Giampietro ^a   Valoti, Massimo ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b CHIRON VACCINES   (Italy)

Author keywords

African green monkey; Brain cytochrome p450 metabolism; C57BL 6 mouse; Deprenyl; Selegiline

Indexed keywords

4 METHYLPYRAZOLE; CYTOCHROME P450; CYTOCHROME P450 2A; CYTOCHROME P450 2E1; CYTOCHROME P450 3A; METHAMPHETAMINE; SELEGILINE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN MICROSOME; CATALYSIS; CERCOPITHECUS; CONTROLLED STUDY; CORPUS STRIATUM; DRUG METABOLISM; FEMALE; METABOLITE; MONKEY; MOUSE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL;

ANIMALIA; CERCOCEBUS; CERCOPITHECUS; CERCOPITHECUS AETHIOPS; STAPHYLOCOCCUS PHAGE 3A;

EID: 0041430708     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2003.01927.x     Document Type: Article

References (35)

1. Birkmayer W., Knoll J., Riederer P., Youdim M. D. H., Hars V. and Marton J. (1985) Increased life expectancy resulting from addition of L-Deprenyl to Madopar treatment in Parkinson's disease: a long-term study. J. Neural. Transm. 64, 113-127.
2. Chinta S. J., Pai H. V., Upadhya S. C., Boyd M. R. and Ravindranath V. (2002) Constitutive expression and localization of the major drug metabolizing enzyme, cytochrome P4502D in human brain. Brain Res. Mol. Brain Res. 103, 49-61.
3. Dragoni S., Bellik L., Frosini M., Sgaragli G., Marini M., Gervasi P. G. and Valoti M. (2003) l-Deprenyl metabolism in monkey (Cercopithecus aethiops) liver microsomes. Xenobiotica 33, 181-195.
4. Finnegan K. T., Skratt J. J., Irwin I., DeLanney L. E. and Langston J. W. (1990) Protection against DSP-4-induced neurotoxicity by deprenyl is not related to its inhibition of MAO B. Eur. J. Pharmacol. 184, 119-126.
5. Gelowitz D. L., Richardson J. S., Wishart T. B., Yu, P. H. and Lai C. T. (1994) Chronic l-deprenyl or l-amphetamine: equal cognitive enhancement, unequal MAO inhibition. Pharmacol., Biochem. Behav. 47, 41-45.
6. Gerlach M., Youdim M. B. H. and Riederer P. (1996) Pharmacology of selegiline. Neurology 47, S137-S145.
7. Grace J. M., Kinter M. T. and Macdonald T. L. (1994) Atypical metabolism of deprenyl and its enantiomer, (S)-(+)-N,alpha-dimethyl-N-propynylphenethylamine, by cytochrome P450 2D6. Chem. Res. Toxicol. 7, 286-290.
8. Hedlund E., Gustafsson J. A. and Warner M. (2001) Cytochrome P450 in the brain; a review. Curr. Drug Metab. 2, 245-263.
9. Hidestrand M., Oscarson M., Salonen J. S., Nyman L., Pelkonen O., Turpeinen M. and Ingelman-Sundberg M. (2001) CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes. Drug Metab. Dispos. 29, 1480-1484.
10. Koenigs L. L., Peter R. M., Thompson S. J., Rettie A. E. and Trager W. F. (1997) Mechanism-based inactivation of human liver cytochrome P4502A6 by 8-methoxypsoralen. Drug Metab. Dispos. 25, 1407-1415.
11. Lajtha A., Sershen H., Cooper T., Hashim A. and Gaal J. (1996) Metabolism of (-)-deprenyl and PF-(-)-deprenyl in brain after central and peripheral administration. Neurochem., Res. 21, 1155-1160.
12. Larsen J. P. and Boas J. (1997) The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian-Danish 5-year study. Norwegian-Danish Study Group. Mov. Disord. 12, 175-182.
13. Lowry O., Rosenbrough N., Farr A. and Randall R. (1951) Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265-275.
14. Maruyama W., Yamamoto T., Kitani K., Carrillo M. C., Youdim M. and Naoi M. (2000) Mechanism underlying anti-apoptotic activity of a (-)deprenyl-related propargylamine, rasagiline. Mech. Ageing Dev. 116, 181-191.
15. McFayden M. C., Melvin W. T. and Murray G. I. (1998) Regional distribution of individual forms of cytochrome P450 mRNA in normal adult human brain. Biochem. Pharmacol. 55, 825-830.
16. Melega W. P., Cho A. K., Schmitz D., Kuczenski R. and Segal D. S. (1999) l-Methamphetamine pharmacokinetics and pharmacodynamics for assessment of in vivo deprenyl-derived l-methamphetamine. J. Pharmacol. Exp. Ther. 288, 752-758.
17. Milgram N. W., Ivy G. O., Murphy M. P., Head E., Wu P. H., Ruehl W. W., Yu P. H., Durden D. A., Davis B. A. and. Boulton A. A. (1995) Effects of chronic oral administration of l-deprenyl in the dog. Pharmacol. Biochem. Behav. 51, 421-428.
18. Naoi M., Maruyama W., Takahashi T., Akao Y. and Nakagawa Y. (2000) Involvement of endogenous N-methyl(R.)salsolinol in Parkinson's disease: induction of apoptosis and protection by (-)deprenyl. J. Neural Transm. Suppl. 58, 111-121.
19. Parkinson A. (1996) Biotransformation of xenobiotics, in Casarett and Doull's Toxicology, the Basic Science of Poisons (Klaassen C. D., ed.), 5th edn, pp. 113-186. Mc Graw-Hill, New York.
20. Paterson I. A. and Tatton W. G. (1998) Anti-apoptotic actions of MAO-B inhibitors. Adv. Pharmacol. 42, 312-315.
21. Reimer M. L., Mamer O. A., Zavitsanos A. P., Siddiqui A. W. and Dadgar D. (1993) Determination of amphetamine, methamphetamine and desmethyldeprenyl in human plasma by gas chromatography/negative ion chemical ionization mass spectrometry. Biol. Mass. Spectrom. 22, 235-242.
22. Sai Y., Dai R., Yang T. Y. J., Krausz K. W., Gonzales F. J., Gelboin H. V. and Shou M. (2000) Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450. Xenobiotica 30, 327-343.
23. Suuronen T., Kolehmainen P. and Salminen A. (2000) Protective effect of l-Deprenyl against apoptosis induced by okadaic acid in cultured neuronal cells. Biochem. Pharmacol. 59, 1589-1595.
24. Szende B., Magyar K. and Szegedi Z. (2000) Apoptotic and antiapoptotic effect of (-)deprenyl and (-)-desmethyl-deprenyl on human cell lines. Neurobiology (Bp) 8, 249-255.
25. Sziráki I., Kardos V., Patthy M., Pátfalusi M., Gaál J., Solti M., Kollár E. and Singer J. (1994) Amphetamine-metabolites of deprenyl involved in protection against neurotoxicity induced by MPTP and 2′-methyl-MPTP. J. Neural Transm. Suppl. 41, 207-219.
26. Taavitsainen P., Anttila M., Nyman L., Karnani H., Salonen J. S. and Pelkonen O. (2000) Selegiline metabolism and cytochrome P450 enzymes: in vitro study in human liver microsomes. Pharmacol. Toxicol. 86, 215-221.
27. Tatton W. G. and Chalmers-Redman R. M. E. (1996) Modulation of gene expression rather than monoamine oxidase inhibition: (-)-Deprenyl-related compounds in controlling neurodegeneration. Neurology 47, S171-S183.
28. Tatton W. G. and Greenwood C. E. (1991) Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J. Neurosci. Res. 30, 666-672.
29. Tatton W. G., Chalmers-Redman R. M., Ju W. J., Mammen M., Carlile G. W., Pong A. W. and Tatton N. A. (2002) Propargylamines induce antiapoptotic new protein synthesis in serum- and nerve growth factor (NGF)-withdrawn, NGF-differentiated PC-12 cells. J. Pharmacol. Exp. Ther. 301, 7537-7564.
30. Tetrud J. W. and Langston J. W. (1989) The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 245, 519-522.
31. The Parkinson Study Group (1989) Effect of deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 321, 1364-1371.
32. The Parkinson Study Group (1993) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 328, 176-183.
33. Tirumalai P. S., Bhamre S., Upadhya S. C., Boyd M. R. and Ravindranath V. (1998) Expression of multiple forms of cytochrome P450 and associated mono-oxygenase activities in rat brain regions. Biochem. Pharmacol. 56, 371-375.
34. Valoti M., Fusi F., Frosini M., Pessina F., Tipton K. F. and Sgaragli G. P. (2000) Cytochrome P450-dependent N-dealkylation of L-deprenyl in C57BL mouse liver microsomes: effects of in vivo pretreatment with ethanol, phenobarbital, beta-naphthoflavone and L-deprenyl. Eur. J. Pharmacol. 391, 199-206.
35. Warner M., Kohler C., Hansson T. and Gustafsson J. A. (1988) Regional distribution of cytochrome P-450 in the rat brain: spectral quantitation and contribution of P-450b,e, and P-450c,d. J. Neurochem. 50, 1057-1065.